Stifel Maintains Buy on Boston Scientific, Lowers Price Target to $90

Benzinga Newsdesk www.benzinga.com Negative 61.8%

Neg 61.8% Neu 0% Pos 0%

Stifel analyst Rick Wise maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $110 to $90.